Cue Biopharma (CUE) Non-Current Debt (2022 - 2025)
Cue Biopharma (CUE) posted Non-Current Debt of $190000.0 for Q3 2025, little changed sequentially from $190000.0 in Q2 2025, and down 81.0% YoY from $1.0 million in Q3 2024.
Cue Biopharma (CUE) Non-Current Debt (2022 - 2025) Analysis & Trends
Cue Biopharma has reported Non-Current Debt for 4 years, with the latest figure at $190000.0 in Q3 2025.
- Quarterly Non-Current Debt fell 81.0% year-over-year to $190000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $190000.0 (down 81.0% YoY) and the FY2023 annual result came in at $4.2 million, down 47.7% from the prior year.
- Non-Current Debt held at $190000.0 in Q3 2025 per CUE's latest filing, from $190000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $9.9 million in Q2 2022 and troughed at $83000.0 in Q3 2022.
- A 4-year average of $4.4 million and a median of $4.2 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt surged 5924.1% in 2023, then sank 91.69% in 2025.
- Over 4 years, Non-Current Debt stood at $8.0 million in 2022, then tumbled by 47.7% to $4.2 million in 2023, then slumped by 76.2% to $1.0 million in 2024, then slumped by 81.0% to $190000.0 in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $190000.0, $190000.0, and $1.0 million for Q3 2025, Q2 2025, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 190,000.00 |
| Jun 30, 2025 | 190,000.00 |
| Sep 30, 2024 | 1.00 Mn |
| Jun 30, 2024 | 2.29 Mn |
| Mar 31, 2024 | 3.24 Mn |
| Dec 31, 2023 | 4.20 Mn |
| Sep 30, 2023 | 5.00 Mn |
| Jun 30, 2023 | 6.00 Mn |
| Mar 31, 2023 | 7.08 Mn |
| Dec 31, 2022 | 8.04 Mn |
| Sep 30, 2022 | 83,000.00 |
| Jun 30, 2022 | 9.91 Mn |
| Mar 31, 2022 | 9.86 Mn |